Target intelligence / Profile preview

Dipeptidyl peptidase-like protein 6 (DPP6)

Target
DPP6
Molecular classification
Ion channel auxiliary subunit, Voltage-gated potassium channel regulator, Transmembrane protein, Dipeptidyl peptidase (non-enzymatic, structurally related)
01

Overview

Dipeptidyl peptidase-like protein 6 (DPP6) is a non-catalytic, transmembrane auxiliary subunit that associates with A-type Kv4 potassium channels in neurons[1][2]. DPP6 strongly influences channel gating, current amplitude, and membrane localization, helping regulate neuronal excitability, action potential backpropagation, and dendritic signaling[1][2][3]. Besides its ion channel modulatory role, DPP6 independently promotes filopodia growth and stability, playing a critical part in synaptic formation and maintenance. DPP6 is associated with several neurological disorders (ALS, dementia, intellectual disability, Tourette’s syndrome, microcephaly, autism spectrum disorder), highlighting its importance in CNS function and development[1]. While not an enzymatically active peptidase, DPP6’s structure is related to dipeptidyl peptidases, underlining its role as a specialized regulator of potassium channel activity and neuronal signaling[1][2][3].

Other names
A-type potassium channel modulatory protein DPP6Dipeptidyl aminopeptidase-like protein 6Dipeptidyl aminopeptidase-related proteinDipeptidyl peptidase VIDPP VIDPPXDPL1Dipeptidyl-peptidase 6VF2MRD33
02

Mechanism of action

Not applicable directly; as an auxiliary subunit, DPP6 modulates potassium channel function, influencing gating kinetics, channel localization, and neuronal excitability[1][2][3].

03

Biological functions

Modulation of A-type (Kv4) potassium channel gating and localization[1][2][3]Enhancement of neuronal excitability and regulation of firing patterns[1]Promotion and stabilization of dendritic filopodia (synaptic development)[1]Regulation of synaptic plasticity[1]
04

Disease associations

Neurodegenerative disease (ALS, dementia)Intellectual disabilityTourette’s syndromeAutism spectrum disorderMicrocephaly[1]
05

Safety considerations

Loss or dysfunction of DPP6 can contribute to neurological disorders, affecting neuronal excitability, synaptic development, and cognitive function; thus, therapeutic modulation poses risks of neurotoxicity, seizure, and impaired cognitive development[1]
06

Biomarkers

DPP6 genetic variants are studied as biomarkers for some neurological disorders, particularly ALS, dementia, and autism spectrum disorder[1]

Beyond the preview

Go deeper on Dipeptidyl peptidase-like protein 6 (DPP6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dipeptidyl peptidase-like protein 6 (DPP6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call